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ABSTRACT   
Objectives:  The influence of hormonal changes due to pregnancy has been well-studied in 
relation to colorectal cancer risk, but the association remains undefined.  The purpose of this 
investigation was to examine the relationship between differences in gravidity and parity, and 
colorectal cancer risk, and whether the association varied by microsatellite instability (MSI), a 
feature more common in women, in a case-control study.  
Methods:  The study population included incident colorectal cancer cases (n=1,014), aged 50-
74 years, diagnosed from 1998-2002 in Washington state and controls (n=1,064) randomly 
selected from population lists.  All study subjects completed telephone interviews to ascertain 
prior pregnancies and live births, and other covariates. Case tissue samples were obtained for 
MSI analyses.  Multivariable logistic regression models estimated odds ratios (OR) and 95% 
confidence intervals (CI), adjusting for age, family history of colorectal cancer, body mass index, 
education, endoscopy screening, oral contraceptive use, hormone therapy use, smoking, and 
alcohol consumption.   
Results:  There was an approximate 30-50% reduction in risk of colon cancer associated with 
gravidity, which was attenuated in the analysis with parity.  Increasing gravidity and parity were 
associated with a suggestion of a decreasing trend in risk for rectal cancer (p-trend=0.07). 
Compared to women who had equal numbers of pregnancies to livebirths, women who were 
nulligravid and nulliparous had 40-60% increased risk of colon cancer.  There was a suggestion 
of a reduced risk of both colon and rectal cancer associated with one more pregnancy than live 
birth.  There was a suggestion of an increased risk of MSI-high tumors with nulligravidity and 
nulliparity.    
Conclusions:  These results confirm the importance of pregnancy events in the etiology of colon 
and rectal cancer.   
 
List of abbreviations:  microsatellite instability MSI 
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INTRODUCTION 
It has been hypothesized that reproductive factors, including increasing numbers of live 
births, reduce the risk of colorectal cancer due to the hormonal changes of pregnancy.1  
However, from observational studies, a consistent association between parity and colorectal 
cancer has not been strongly evident.2-15  Some studies have demonstrated a 20-40% reduction 
in colorectal cancer risk at 4-5 live births compared to nulliparous women,2,4,6,10 whereas most 
epidemiologic studies have detected no association with increasing parity.3,5,7-9,11,12,15  When 
results are stratified by site, there has been no clear pattern in the association between parity 
and either colon or rectal cancer. 
Only two studies have reported on the role of any pregnancy, including those that either 
resulted in live birth or ended in miscarriage, tubal pregnancy, or induced abortion.2,3 One study 
suggested an elevated colorectal cancer risk with increasing number of pregnancies,3 whereas 
the second suggested a 16% decreased risk associated with five or more pregnancies.2  A 
pregnancy lasting less than 6 months might also influence colorectal cancer risk through 
hormonal changes but would not contribute to the assessment of total parity.  Thus, gravidity 
might be a more comprehensive evaluation of the role of both incomplete and complete 
pregnancies.   
The purpose of this analysis was to evaluate the roles of gravidity and parity, separately, 
and together on colorectal cancer risk.  We specifically addressed whether there were any 
differences in association between a full-term pregnancy and any pregnancy.  Further, we 
examined the association between gravidity and parity by microsatellite instability (MSI) status, 
a phenotype that tends to be more common in women than in men.   
 
MATERIALS AND METHODS 
Eligible case subjects included all women aged 50-74 years, residing in 13 counties in 
western Washington state, who were diagnosed between 1998-2002 with incident invasive 
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colorectal adenocarcinoma [International Classification of Diseases for Oncology codes C18.0, 
C18.2-18.9, C19.9, C20.0-20.9].16  Cases were reported to the Cancer Surveillance System, a 
population-based registry that is part of the National Cancer Institute's Surveillance, 
Epidemiology, and End Results (SEER) program.  Eligibility for this study was limited to English-
speaking subjects with available telephone numbers and without a prior personal history of 
colorectal cancer.  
After the cases were identified (usually within 4 months of diagnosis), physicians were 
contacted about their patients’ eligibility for this study.  If the physicians had no objection to 
participation, an introductory letter was mailed to the case subject and followed-up with a 
telephone call.   
Community-based control women were randomly selected according to the age 
distribution (5-year age-intervals) of the eligible cases using lists of licensed drivers from the 
Washington State Department of Licensing for women aged 50-64 years, and rosters from the 
Health Care Financing Administration (currently the Centers for Medicare and Medicaid) for 
women 65 years and older.   
 A structured 60-minute telephone interview was used to obtain information from all study 
participants on possible reproductive risk factors for colorectal cancer.  Questions included total 
number of pregnancies (i.e., miscarriages, stillbirths, tubal pregnancies and abortions); number 
of pregnancies lasting 6 months or more; number of pregnancies resulting in a live birth; and 
ages at first and last live birth. The interview also elicited use of exogenous hormones, 
menstrual history, smoking history, height and weight, endoscopy screening (including a 
colonoscopy and/or sigmoidoscopy), first-degree family history of cancer, and demographic 
factors.  We interviewed 1014 cases (73% response) and 1064 control subjects (66% 
response).  
 The study was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center in accordance with assurances filed with and approved by the U.S. 
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Department of Health and Human Services.  Informed consent was obtained from all 
participants. 
Pathology Materials  
We were able to obtain the release of paraffin-embedded colorectal tumor tissue and 
diagnostic pathology reports for 90% of consenting cases (n=648).  Sections were cut from the 
most representative tumor and normal tissue blocks, and stained with hematoxylin and eosin 
(H&E).  Stained sections were reviewed by a pathologist, who selected for further sectioning a 
block of normal tissue and a block with colorectal tumor consisting of approximately 80% of the 
tissue.  DNA was extracted from tumor and normal tissue using tissue DNA extraction kits from 
QIAGEN (QIAGEN, Inc, Valencia, CA). 
Microsatellite Instability (MSI) Analysis  
MSI testing was completed on 590 tumors with sufficient tissue using a standard panel:  
four mononucleotide markers (BAT25, BAT26, BAT40, BAT34C4), four dinucleotide repeats 
(ACTC, D5S346, D18S55, and D10197), and one complex marker (MYCL).  This panel included 
the five recommended markers in the panel proposed during the National Cancer Institute 
workshop on microsatellite instability for cancer detection.17  PCR fragments were tagged with a 
fluorescent dye and analyzed on an ABI3100 generic analyzer, using a previously described 
protocol.18  For all of the cases, we corroborated the MSI results with immunohistochemistry 
testing for hMLH1, hMSH2, and hMSH6. In a round-robin reading by pathologists of MSI status 
in six laboratories, this approach and interpretation was highly reproducible.19 
Definitions and Statistical Analysis  
Gravidity was defined as the sum of all pregnancies, including all live births and 
pregnancies which terminated at less than 6 months or did not result in a live birth.  Parity was 
defined as pregnancies that resulted in the delivery at 6 month or more gestation, either 
resulting in a live birth or a stillbirth. 
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To assess the relationship between differences in gravidity and parity, a categorical 
variable was created as follows:  nulligravid, nulliparous, 0 (number of pregnancies equals the 
number of live births), 1 (woman had one more pregnancy than live birth), and 2+ (woman had 
two or more pregnancies than live births).  Nulligravid and nulliparous were considered mutually 
exclusive categories. 
Women who reported a colonoscopy and/or sigmoidoscopy which occurred at least two 
years prior to the diagnosis date for cases and the interview date for controls were considered 
to have been screened via endoscopy for colorectal cancer. 
Tumors were classified as microsatellite stable-low (0 to <30 % of loci unstable), or MSI-
high (≥ 30 percent of loci unstable); unequivocal results for at least 5 markers were required in 
order to classify a tumor’s MSI status.17 
Odds ratios (OR) and 95% confidence intervals (CI) for the association between 
reproductive risk factors and colorectal cancer incidence were estimated using logistic 
regression models, adjusting for age (in 5-year intervals), first-degree family history of colorectal 
cancer, body mass index (BMI, kg/m2), education, endoscopy screening, oral contraceptive use, 
hormone therapy, smoking status, and alcohol consumption.  Results are presented for 
colorectal cancer cases combined and also stratified by site within the bowel.  The sum of the 
colon and rectal cancer do not equal the total colorectal cancer, due to cases missing site 
information (n=2) and cases with diagnostic code C19.9 (large bowel) which could not be further 
classified (n=73).  Tests of trend were conducted by including the variable in the model as an 
ordinal variable.  All statistical analyses were performed using SAS v8.2 (SAS Institute Inc, 
Cary, NC); all statistical significance tests were two-sided.  
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RESULTS 
Cases were more likely than controls to have a high school degree or less, a first-degree 
family history of colorectal cancer, a higher BMI, to be current smokers, and to not use hormone 
therapy (Table 1).     
 There were few strong associations between reproductive factors and colorectal cancer 
risk (Table 2).  Approximately 9% of cases and 7% of controls were nulligravid.  Overall, there 
was a decreasing risk of colorectal cancer associated with gravidity.  There was a statistically 
significant decreasing trend in risk of colon cancer associated with increasing gravidity; 
however, there was an approximately 30-50% reduction in risk across all categories of numbers 
of pregnancies.  The results by parity were attenuated and imprecise, but demonstrating a 
reduced risk across the categories of live birth (Table 2).  There were suggestions of statistically 
dose-response relationships between increasing gravidity and parity and reduced risk of rectal 
cancer.  Women who had an early first birth had a borderline statistically significant increase risk 
of colon cancer, but not rectal cancer.  There were no associations between colorectal cancer 
risk and ages at menarche and last birth (Table 2).    
 Compared to women who had an equal number of pregnancies to live births, women 
who were nulligravid and nulliparous had an approximately 40-60% elevated risk of colon 
cancer, but no increased risk of rectal cancer (Table 3).  Among women with one more 
pregnancy than live birth, there was a statistically significant 24% reduced risk of colon cancer; 
there was no evidence of a reduced risk among women with 2 or more pregnancies than 
number of live births.  For rectal cancer, there were no statistically significant associations with 
nulligravidity and nulliparity.  Similar to colon cancer, there was a 25% reduction in risk 
associated with one more pregnancy than live birth, but this association was not statistically 
significant (Table 3).  There was no statistical difference between the pattern of associations 
with colon cancer compared to rectal cancer (Wald p-value=0.7) 
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 There was a non-significant increased risk of MSI-high colorectal cancer among women 
who were nulligravid or nulliparous, although the estimates were imprecise due to small 
numbers (Table 4).  There were no associations between MSI-stable/MSI-low tumors by 
gravidity:parity. 
 
DISCUSSION 
Overall, we detected a reduction in risk of colon and rectal cancer independently 
associated with gravidity, which attenuated for parity.  For rectal cancer, the observed 
decreased risk is not evident until either the second or subsequent pregnancy or live birth, 
although this relationship was not statistically significant.  Compared to women with equivalent 
gravidity and parity, there was an increased risk of colon cancer but not rectal cancer 
associated with being nulligravid or nulliparous.  There was a decreased risk of colon and rectal 
cancer associated with one more pregnancy than live birth.  
 The majority of studies investigating increasing parity in relation to colon cancer have 
detected no association.3,5,7-15  In our study, we demonstrated a step-function reduction in colon 
cancer risk with the first pregnancy.  While the p-trend reported was statistically significant, 
when we excluded the baseline category, the p-trend was no longer statistically significant.  
These results suggest that the hallmark of a first pregnancy or live birth might be sufficient to 
decrease colon cancer.     
Most studies have shown no association between increasing parity and rectal cancer.6-
8,10,15,20,21   To our knowledge, no studies have reported the role of gravidity alone in relation to 
rectal cancer.  We detected a decreasing trend in risk associated with increasing pregnancies, 
though not statistically significant, as well as a reduced risk of rectal cancer associated with a 
higher difference in gravidity to parity.   
Changes in maternal hormones during pregnancy might lead to etiologic changes which 
affect colon and rectal cancer risk.  Estradiol and estriol are produced by the placenta, and 
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maternal levels continue to increase over the course of the pregnancy.22  It is hypothesized that 
the role of estrogen might influence cellular proliferation, but it has also been shown to inhibit 
growth of the colon.  For example, estrogen has been shown to reduce bile acids, decrease the 
growth enhancing of insulin-like growth factors (IGFs), and maintain the transcription and 
expression of estrogen and progesterone receptors.23     Exogenous hormone therapy use, 
specifically estrogen plus progestin, is associated with a reduction in risk of both colon and 
rectal cancer.24  
Further, hormonal changes in prolactin levels are different between nulliparous and 
nulligravid women from parous women.  Serum prolactin levels increase during pregnancy, but 
then decrease after birth even among breastfeeding mothers.22  Parous women have been 
found to have low levels of prolactin following pregnancy, and the effect can last as long as 12-
13 years after pregnancy.  Conversely, nulliparous women have higher levels of prolactin.25  
Women with colorectal cancer tend to have higher levels of prolactin compared to similarly-aged 
controls,26 and the tumor is not the likely source of the increased prolactin levels.27  Therefore, 
the combination of maternal hormones as a result pregnancy is likely to alter the risk of 
colorectal cancer.  
In addition to hormonal changes due to pregnancy, there are physical changes which 
also occur.  Any pregnancy results in pelvic crowding due to increased uterine size.  As a result 
of pregnancy, the uterus does not return to its prior size.  The pressure of pelvic crowding might 
affect the rectum differently than the colon.  Increased pressure on the rectum could lead to 
increased bowel movements, which might reduce rectal cancer risk.  Frequent pelvic crowding 
due to pregnancy might explain the reduction in risk with rectal cancer. 
 There is emerging evidence that there are etiologic differences between proximal and 
distal colon cancer and rectal cancer.  Colon and rectal tumors differ by their embryologic 
source and function, sex differences, and risk factors (e.g., alcohol consumption and physical 
activity).28  In regards to sex differences, women have a larger proportion of proximal tumors 
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compared to men.  Further, proximal tumors are more likely to have epigenetic changes 
compared to distal or rectal tumors, suggesting that a hormonal component might be 
etiologically relevant in these tumors.23  Estradiol has also been associated with epigenetic 
changes in carcinogenesis,29 and hence increasing parity and gravidity would result in lower 
lifetime estradiol exposure.  Slattery et al. demonstrated that colorectal cancer cases who were 
MSI-high were more likely to be nulligravid (16.4%) compared to controls (8.3%) or MSI-stable 
or –low (7.6%).30  In our study, we were not able to fully confirm these results; we detected that 
6.5% of MSI-high cases were nulligravid compared to 8.4% of MSI-stable/low cases and 7% of 
controls.  We were able to demonstrate an increased risk of MSI-High tumors among 
nulliparous or nulligravid women, but these results were not statistically significant.  Further 
studies should attempt to replicate these findings. 
Our analysis was limited in several ways.  First, there were only 188 rectal cancer 
detected during the study, limiting the statistical power in the study.  Our sample, though, 
reflects the overall distribution of colorectal cancer in the US population.31   Larger studies might 
be able to detect statistically significant associations between parity and gravidity and rectal 
cancer.  There is the possibility of recall bias, but as our main measures of association were 
reproductive events, which are highly recalled by mothers.32  Cases and controls were asked to 
report on a variety of screening mechanisms.  We report in this analysis the combination of 
either a sigmoidoscopy or colonoscopy, which are the most common efficacious screening 
tests.  The large size of the study, its population-based design, and standardized assessment 
lend confidence to our findings. 
Changes in reproductive events might have long-term impact on colorectal cancer rates.  
The prevalence of nulligravid and nulliparous women is changing within the US as more women 
choose to not to have children.  In a recent US cohort study, the prevalence of nulliparity has 
increased from 18 to 34% from 1975 to 1995.33  This changing demographic of childbearing has 
already impacted breast cancer incidence.34  Prior investigations of reproductive factors and 
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colorectal cancer might consider reanalyzing their data to determine if these findings with 
gravidity and parity are consistent across other populations, in particular with respect to MSI 
status. 
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TABLE 1.  Demographic characteristics of female colorectal cancer cases and controls. 
  Colorectal cancera 
 
Control 
(n=1064) 
N (%) 
All 
(n=1014) 
N (%) 
Colon cancer 
(n=751) 
N (%) 
Rectal cancer
(n=188) 
N (%) 
Age (years)     
  50-54 145 (13.6) 145 (14.3) 92 (12.2) 41 (21.8)b 
  55-59 156 (14.7) 160 (15.8) 115 (15.3) 30 (16.0) 
  60-64 181 (17.0) 181 (17.9) 128 (17.0) 36 (19.1) 
  65-69 308 (28.9) 241 (23.8) 183 (24.4) 43 (22.9) 
  70-74 274 (25.7) 287 (28.3) 233 (31.0) 38 (20.2) 
     
Education     
  Less than high school 60 (5.6) 104 (10.2) b 85 (11.0) b 13 (7.7) 
  High school diploma 346 (32.5) 371(36.8) 275 (36.6) 64 (35.3) 
  Some college 321 (30.2) 294 (29.2) 206 (27.8) 65 (34.6) 
  College degree or higher 337 (31.7) 244 (23.8) 185 (24.6) 45 (22.4) 
     
Family history of colorectal cancer    
  No 949 (89.2) 840 (82.7) b 617 (82.1) b 156 (81.6) b 
  Yes 115 (10.8) 174 (17.3) 134 (17.9) 32 (18.4) 
     
BMI (kg/m2)     
<25 482 (45.5) 386 (38) b 281 (37.1) b 76 (40.2) 
25-29.9 344 (32.5) 319 (31.5) 241 (32) 56 (31.5) 
>=30 233 (22.0) 307 (30.5) 227 (30.9) 56 (28.3) 
     
Endoscopy screeningc     
  Never 551 (53.0) 700 (71.8) b 493 (68.9) b 150 (81.4) b 
  Ever  489 (47.0) 273 (28.2) 225 (31.1) 32 (18.6) 
     
Oral contraceptive use     
   Never 508 (53.1) 563 (56.9) 425 (56.6) 102 (59.9) 
   Ever 449 (46.9) 436 (43.1) 314 (43.4) 86 (40.1) 
     
     
15 
16 
Hormone replacement therapy     
  Never users 414 (39.0) 454 (44.8) b 338 (44.7) b 78 (42.1) 
  Former users 134 (12.6) 147 (14.7) 106 (14.6) 34 (18.3) 
  Current users 514 (48.4) 403 (40.4) 298 (40.8) 75 (39.6) 
     
Smoking status     
  Never  500 (52.2) 460 (45.8) b 341 (45.9) b 79 (41.9) b 
  Former 340 (35.5) 382 (38.2) 288 (38.9) 72 (38.7) 
  Current 117 (12.2) 161 (16) 113 (15.3) 37 (19.4) 
     
Alcohol consumption (per week)    
  Never  552 (58.2) 633 (63.7) 473 (64.4) b 113 (60.1) 
  1-6 drinks 222 (23.4) 195 (19.6) 143 (19.5) 37 (19.9) 
  7 drinks 47 (5.0) 37 (3.8) 22 (2.9) 11 (6.4) 
  >7 drinks 128 (13.5) 128 (12.9) 96 (13.1) 26 (13.7) 
aPercentages are age-adjusted to the distribution of controls. 
bp-value<0.05. 
cEndoscopy screening includes a colonoscopy or sigmoidoscopy at least two years prior to diagnosis date for cases and interview 
date for controls. 
 
TABLE 2. Odds ratios and 95% confidence intervals for colorectal cancer in relation to 
reproductive risk factors.   
  Colorectal cancera 
 Controls All Colon cancer Rectal cancer  
Characteristic N (%) N (%) OR (95% CI)b N (%) OR (95% CI)b N (%) OR (95% CI)b 
Age at menarche 
(years) 
       
  <12 168 (17.8) 206 (20.9) 1.00 (reference) 151 (20.8) 1.00 (reference) 45(24.3) 1.00 (reference)
  12 239 (25.3) 241 (24.4) 0.87 (0.65-1.16) 178 (24.6) 0.89 (0.65-1.21) 50(26.1) 0.89 (0.55-1.44)
  13 282 (29.8) 261 (26.5) 0.82 (0.62-1.08) 190 (26.0) 0.82 (0.60-1.11) 51(28.5) 0.73 (0.45-1.19)
  14+ 256 (27.1) 278 (28.2) 0.97 (0.73-1.28) 211(28.6) 0.99 (0.73-1.35) 37(21.1) 0.62 (0.37-1.04)
  P trend   0.9  0.9  0.06 
        
Gravidity        
  Nulligravid 68 (7.1) 95 (9.4) 1.00 (reference) 75 (10.1) 1.00 (reference) 17(9.1) 1.00 (reference)
  1 67 (7.0) 70 (6.9) 0.75 (0.46-1.20) 49 (6.6) 0.63 (0.38-1.06) 14(6.2) 0.98 (0.42-2.26)
  2 199 (20.8) 225 (22.3) 0.75 (0.51-1.10) 163 (22.1) 0.68 (0.45-1.02) 45(24.8) 0.85 (0.43-1.68)
  3 226 (23.6) 212 (21.1) 0.64 (0.43-0.94) 149 (20.1) 0.55 (0.37-0.84) 47(24.2) 0.84 (0.43-1.65)
  4 181 (18.9) 158 (15.8) 0.55 (0.36-0.82) 119 (15.9) 0.50 (0.33-0.77) 26(14.5) 0.57 (0.27-1.19)
  5+ 216 (22.6) 243 (24.4) 0.66 (0.45-0.98) 187 (25.0) 0.62 (0.41-0.94) 39(21.2) 0.65 (0.32-1.33)
  P trend   0.02  0.03  0.08 
        
Parityc        
  Nulliparous 87 (9.1) 118 (11.7) 1.00 (reference) 93 (12.5) 1.00 (reference) 21(10.9) 1.00 (reference)
  1 89 (9.3) 102  (10.1) 0.88 (0.44-1.77) 71 (9.7) 0.75 (0.35-1.58) 21(10) 1.09 (0.31-3.86)
  2 282 (29.5) 283 (28.1) 0.80 (0.41-1.53) 198 (26.8) 0.69 (0.34-1.38) 63(33) 0.99 (0.3-3.29) 
  3 252 (26.3) 230 (23.0) 0.72 (0.37-1.39) 173 (23.3) 0.66 (0.32-1.34) 42(22.6) 0.78 (0.23-2.65)
  4 143 (14.9) 145 (14.5) 0.70 (0.35-1.39) 111 (14.9) 0.65 (0.31-1.35) 22(12.5) 0.59 (0.16-2.12)
  5+ 104 (10.9) 125 (12.6) 0.79 (0.39-1.59) 96 (12.7) 0.74 (0.35-1.57) 19(11) 0.71 (0.19-2.59)
P trend   0.3  0.7  0.07 
        
Age at first birth (years)       
  <20 167 (19.3) 239 (27.2) 1.25 (0.96-1.63) 185 (28.6) 1.31 (0.99-1.74) 39(23.4) 1.09 (0.67-1.77)
  20 - <25 429 (49.5) 411(46.7) 1.00 (reference) 297 (45.8) 1.00 (reference) 83(49) 1.00 (reference)
  25 - <30 197 (22.7) 163 (18.3) 0.95 (0.72-1.24) 114 (17.6) 0.89 (0.66-1.2) 34(20.5) 1.03 (0.63-1.67)
  30+ 74 (8.5) 69 (7.8) 1.06 (0.72-1.56) 52 (8) 1.06 (0.7-1.61) 10(7.1) 0.8 (0.37-1.72) 
  P trend   0.3  0.1  0.6 
        
Age at last birth (years)       
17 
18 
  < 20 7 (0.9) 7 (0.9) 0.59 (0.19-1.85) 3 (0.5) 0.30 (0.07-1.30) 2 (1.2) 1.05 (0.16-7.09)
  20-24 114 (14.6) 153 (19.6) 1.00 (reference) 113 (19.8) 1.00 (reference) 31 (20.5) 1.00 (reference)
  25-29 277 (35.5) 264 (33.8) 0.75 (0.55-1.03) 194 (33.8) 0.77 (0.55-1.07) 51 (35.4) 0.69 (0.40-1.18)
  30-34 247 (31.7) 235 (30.2) 0.77 (0.56-1.06) 171 (29.6) 0.74 (0.52-1.05) 42 (29.9) 0.68 (0.38-1.22)
  35+ 135 (17.3) 122 (15.6) 0.74 (0.51-1.07) 96 (16.3) 0.77 (0.51-1.15) 19 (13) 0.62 (0.31-1.23)
  P trend   0.2  0.3  0.2 
a Percentages are age-adjusted to the distribution of controls. 
bAdjusted for age, family history of colorectal cancer, BMI, education, endoscopy screening, oral contraceptive use, hormone 
replacement therapy, smoking, and alcohol consumption. 
cAdditional adjustment for gravidity. 
 
 
TABLE 3.  Associations between differences in gravidity and parity and risk of colorectal cancer. 
   
  Colorectal Cancer 
 Controls All Colon cancer Rectal cancer 
Gravidity:Parity N (%) N (%) OR (95% CI)a N (%) OR (95% CI)a N (%) OR (95% CI)a 
  Nulligravid 68 (7.1) 95 (9.4) 1.42 (0.99-2.02) 75 (10.1) 1.59 (1.09-2.31) 17 (9.1) 1.20 (0.64-2.25) 
  Nulliparous 19 (2.0) 23 (2.3) 1.20 (0.63-2.3) 18 (2.4) 1.36 (0.68-2.71) 4 (1.7) 1.03 (0.31-3.38) 
  0  504 (52.7) 546 (54.5) 1.00 (Reference) 398 (53.7) 1.00 (Reference) 105 (57.5) 1.00 (Reference) 
  1 240 (25.1) 207 (20.6) 0.77 (0.61-0.97) 148 (19.9) 0.76 (0.58-0.98) 38 (20.1) 0.75 (0.49-1.14) 
  2+ 126 (13.2) 132 (13.2) 0.96 (0.72-1.27) 103 (13.9) 1.01 (0.74-1.37) 24 (11.5) 0.93 (0.55-1.57) 
  P trend   0.01  .009  0.265 
aAdjusted for age, family history of colorectal cancer, BMI, education, endoscopy screening, oral contraceptive use, hormone replacement therapy, smoking, 
and alcohol consumption. 
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TABLE 4.   Association between colorectal cancer and selected reproductive 
characteristics by microsatellite instability. 
 MSI-H MSI-L/MSS 
 Cases  Cases  
 N (%)
 OR (95% CI)a N (%) OR (95% CI)a 
Gravidity:Parity     
  Nulligravid 9 (6.6) 1.36 (0.62-2.99) 37(8.4) 1.19 (0.75-1.9) 
  Nulliparous 3 (1.8) 1.32 (0.35-4.96) 7(1.6) 0.81 (0.32-2.05) 
  0  77 (58.3) 1.00 (reference) 239(54.3) 1.00 (reference) 
  1 31 (20.4) 0.85 (0.53-1.36) 96(22) 0.80 (0.59-1.08) 
  2+ 18 (12.9) 0.94 (0.53-1.68) 61(13.7) 1.04 (0.72-1.49) 
p-trend  0.3  0.2 
aAdjusted for age, family history of colorectal cancer, BMI, education, endoscopy screening, oral contraceptive use, 
hormone replacement therapy, smoking, and alcohol consumption. 
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